NRx Pharmaceuticals Advances KETAFREE Approval Timeline to Summer 2026

NRx Pharmaceuticals (NASDAQ: NRXP) aims for summer 2026 approval of its preservative-free ketamine product, KETAFREE. The company has initiated commercial manufacturing and is scaling production capacity up to one million units per batch.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · May 18, 2026, 14:03 UTC

NRx Pharmaceuticals Advances KETAFREE Approval Timeline to Summer 2026

Topics: ketamine therapy NRX-101 pharmaceuticals

Read the full article at Seeking Alpha

More World news

Nvidia CEO Jensen Huang Ousted Amid Allegations of Personal Misconduct and National Security Concerns TechCrunch · November 12, 2026, 16:32 UTC
Pomerantz Law Firm Investigates Silvercorp Metals Inc. Following Production Shortfalls and Revenue Decline PR Newswire · November 12, 2026, 16:30 UTC
Cold Spring Harbor Laboratory Raises $6.5 Million at 21st Annual Double Helix Medals Dinner PR Newswire · November 12, 2026, 16:30 UTC
Deloitte Recognized as Leader in IDC MarketScape Worldwide Digital Identity Services Assessment PR Newswire · November 12, 2026, 16:30 UTC
SpaceX Announces $74 Billion Investment in AI Data Center Projects in Texas and Arizona Seeking Alpha · November 12, 2026, 16:25 UTC
Ofcom Fines Meta £450,000 Over Inaccurate WhatsApp Business Data Seeking Alpha · November 12, 2026, 16:25 UTC
USPS Seeks 11% Fuel Surcharge for Domestic Priority Mail and Package Deliveries CNBC · November 12, 2026, 16:17 UTC
Joe Lavis Named to D CEO's 2027 Dallas 500 List PR Newswire · November 12, 2026, 16:26 UTC
Sanmina Corporation (SANM) Shares Rise 8% Amid Five-Day Winning Streak Seeking Alpha · November 12, 2026, 16:23 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal and National Security Concerns Motley Fool · November 12, 2026, 16:17 UTC